SCTX
Scribe Therapeutics Inc. Common Stock
Price Chart
Latest Quote
$21.65
+6.65 (+44.33%)
Current Price
| Previous Close | $15.00 |
| Open | $25.00 |
| Day High | $25.49 |
| Day Low | $21.00 |
| Volume | 978,946 |
Stock Information
| Shares Outstanding | 16.18M |
| Total Debt | $46.33M |
| Cash Equivalents | $49.73M |
| Revenue | $36.28M |
| Net Income | $-35.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| EPS (TTM) | $-4.24 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $170.03M |
| Sales | $36.28M |
| Income | $-35.73M |
| Cash/sh | $3.07 |
| Employees | 89 |
Financial Ratios
| Quick Ratio | 0.64 |
| Current Ratio | 0.66 |
Returns & Margins
| Gross Margin | -54.65% |
| Operating Margin | -556.52% |
| Profit Margin | -98.48% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
| Recommendation | none |
Technical Indicators
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-24 | $22.00 | 979,321 |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $51,174,000 | $27,413,000 |
| Operating Revenue | $51,174,000 | $27,407,000 |
| Expenses | ||
| Interest Expense | $2,393,000 | $2,381,000 |
| Total Expenses | $77,244,000 | $70,242,000 |
| Other Income Expense | $1,527,000 | $1,495,000 |
| Other Non Operating Income Expenses | $1,527,000 | $1,495,000 |
| Net Non Operating Interest Income Expense | $933,000 | $3,773,000 |
| Interest Expense Non Operating | $2,393,000 | $2,381,000 |
| Operating Expense | $77,244,000 | $70,242,000 |
| General And Administrative Expense | $16,449,000 | $13,163,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-21,808,000 | $-47,786,000 |
| Net Interest Income | $933,000 | $3,773,000 |
| Interest Income | $3,326,000 | $6,154,000 |
| Normalized Income | $-21,808,000 | $-47,786,000 |
| Net Income From Continuing And Discontinued Operation | $-21,808,000 | $-47,786,000 |
| Total Operating Income As Reported | $-26,070,000 | $-42,829,000 |
| Net Income Common Stockholders | $-21,808,000 | $-47,786,000 |
| Net Income | $-21,808,000 | $-47,786,000 |
| Net Income Including Noncontrolling Interests | $-21,808,000 | $-47,786,000 |
| Net Income Continuous Operations | $-21,808,000 | $-47,786,000 |
| Pretax Income | $-23,610,000 | $-37,561,000 |
| Interest Income Non Operating | $3,326,000 | $6,154,000 |
| Operating Income | $-26,070,000 | $-42,829,000 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,140,000 | $-32,291,000 |
| Reconciled Depreciation | $3,077,000 | $2,889,000 |
| EBITDA (Bullshit earnings) | $-18,140,000 | $-32,291,000 |
| EBIT | $-21,217,000 | $-35,180,000 |
| Diluted NI Availto Com Stockholders | $-21,808,000 | $-47,786,000 |
| Tax Provision | $-1,802,000 | $10,225,000 |
| Research And Development | $60,795,000 | $57,079,000 |
| Selling General And Administration | $16,449,000 | $13,163,000 |
| Other Gand A | $16,449,000 | $13,163,000 |
Fetched: 2026-07-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-143,419,000 | $-125,859,000 |
| Total Assets | $78,219,000 | $127,971,000 |
| Total Non Current Assets | $11,285,000 | $17,597,000 |
| Other Non Current Assets | $1,213,000 | $4,420,000 |
| Current Assets | $66,934,000 | $110,374,000 |
| Prepaid Assets | $1,621,000 | $1,688,000 |
| Receivables | $7,350,000 | $3,515,000 |
| Other Receivables | $7,110,000 | $3,232,000 |
| Taxes Receivable | $0 | $15,000 |
| Accrued Interest Receivable | $240,000 | $268,000 |
| Cash Cash Equivalents And Short Term Investments | $57,963,000 | $105,171,000 |
| Cash And Cash Equivalents | $12,796,000 | $12,602,000 |
| Debt | ||
| Net Debt | $22,543,000 | $21,871,000 |
| Total Debt | $41,428,000 | $41,677,000 |
| Long Term Debt And Capital Lease Obligation | $4,804,000 | $40,561,000 |
| Current Debt And Capital Lease Obligation | $36,624,000 | $1,116,000 |
| Current Debt | $35,339,000 | - |
| Other Current Borrowings | $35,339,000 | - |
| Long Term Debt | - | $34,473,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $221,638,000 | $253,830,000 |
| Total Non Current Liabilities Net Minority Interest | $152,581,000 | $218,811,000 |
| Other Non Current Liabilities | $7,485,000 | $8,882,000 |
| Non Current Deferred Liabilities | $19,936,000 | $49,012,000 |
| Current Liabilities | $69,057,000 | $35,019,000 |
| Other Current Liabilities | $66,000 | $87,000 |
| Current Deferred Liabilities | $21,087,000 | $23,407,000 |
| Payables And Accrued Expenses | $6,915,000 | $6,907,000 |
| Payables | $4,566,000 | $4,428,000 |
| Total Tax Payable | $0 | $638,000 |
| Accounts Payable | $4,566,000 | $3,790,000 |
| Equity | ||
| Common Stock Equity | $-143,419,000 | $-125,859,000 |
| Total Equity Gross Minority Interest | $-143,419,000 | $-125,859,000 |
| Stockholders Equity | $-143,419,000 | $-125,859,000 |
| Gains Losses Not Affecting Retained Earnings | $35,000 | $72,000 |
| Other Equity Adjustments | $35,000 | $72,000 |
| Retained Earnings | $-157,707,000 | $-135,899,000 |
| Preferred Securities Outside Stock Equity | $120,356,000 | $120,356,000 |
| Other | ||
| Tangible Book Value | $-143,419,000 | $-125,859,000 |
| Invested Capital | $-108,080,000 | $-91,386,000 |
| Working Capital | $-2,123,000 | $75,355,000 |
| Capital Lease Obligations | $6,089,000 | $7,204,000 |
| Total Capitalization | $-143,419,000 | $-91,386,000 |
| Additional Paid In Capital | $14,239,000 | $9,954,000 |
| Capital Stock | $14,000 | $14,000 |
| Common Stock | $14,000 | $14,000 |
| Non Current Deferred Revenue | $19,936,000 | $49,012,000 |
| Long Term Capital Lease Obligation | $4,804,000 | $6,088,000 |
| Current Deferred Revenue | $21,087,000 | $23,407,000 |
| Current Capital Lease Obligation | $1,285,000 | $1,116,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,365,000 | $3,502,000 |
| Current Accrued Expenses | $2,349,000 | $2,479,000 |
| Net PPE | $10,072,000 | $13,177,000 |
| Accumulated Depreciation | $-10,927,000 | $-7,880,000 |
| Gross PPE | $20,999,000 | $21,057,000 |
| Leases | $4,939,000 | $4,939,000 |
| Other Properties | $14,832,000 | $14,897,000 |
| Machinery Furniture Equipment | $1,228,000 | $1,221,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $45,167,000 | $92,569,000 |
Fetched: 2026-07-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-46,484,000 | $-46,584,000 |
| Operating Activities | ||
| Operating Cash Flow | $-45,213,000 | $-45,235,000 |
| Cash Flow From Continuing Operating Activities | $-45,213,000 | $-45,235,000 |
| Operating Gains Losses | $6,000 | $122,000 |
| Investing Activities | ||
| Capital Expenditure | $-1,271,000 | $-1,349,000 |
| Investing Cash Flow | $45,265,000 | $13,013,000 |
| Cash Flow From Continuing Investing Activities | $45,265,000 | $13,013,000 |
| Financing Activities | ||
| Financing Cash Flow | $142,000 | $-222,000 |
| Cash Flow From Continuing Financing Activities | $142,000 | $-222,000 |
| Net Other Financing Charges | - | $-690,000 |
| Other | ||
| Income Tax Paid Supplemental Data | $208,000 | $1,977,000 |
| End Cash Position | $13,471,000 | $13,277,000 |
| Beginning Cash Position | $13,277,000 | $45,721,000 |
| Changes In Cash | $194,000 | $-32,444,000 |
| Proceeds From Stock Option Exercised | $142,000 | $468,000 |
| Net Investment Purchase And Sale | $46,536,000 | $14,362,000 |
| Sale Of Investment | $104,703,000 | $138,408,000 |
| Purchase Of Investment | $-58,167,000 | $-124,046,000 |
| Net PPE Purchase And Sale | $-1,271,000 | $-1,349,000 |
| Purchase Of PPE | $-1,271,000 | $-1,349,000 |
| Change In Working Capital | $-36,394,000 | $-5,220,000 |
| Change In Other Working Capital | $-31,395,000 | $-6,777,000 |
| Change In Other Current Liabilities | $-2,512,000 | $7,916,000 |
| Change In Other Current Assets | $96,000 | $-13,000 |
| Change In Payables And Accrued Expense | $1,185,000 | $-4,441,000 |
| Change In Accrued Expense | $-365,000 | $-2,525,000 |
| Change In Payable | $1,550,000 | $-1,916,000 |
| Change In Account Payable | $1,550,000 | $-1,916,000 |
| Change In Prepaid Assets | $208,000 | $-439,000 |
| Change In Receivables | $-3,976,000 | $-1,466,000 |
| Other Non Cash Items | $6,459,000 | $2,775,000 |
| Stock Based Compensation | $4,144,000 | $2,849,000 |
| Unrealized Gain Loss On Investment Securities | $-1,527,000 | $-1,495,000 |
| Amortization Of Securities | $830,000 | $631,000 |
| Depreciation Amortization Depletion | $3,077,000 | $2,889,000 |
| Depreciation And Amortization | $3,077,000 | $2,889,000 |
| Depreciation | $3,077,000 | $2,889,000 |
| Gain Loss On Sale Of PPE | $6,000 | $122,000 |
| Net Income From Continuing Operations | $-21,808,000 | $-47,786,000 |
Fetched: 2026-07-25